学士，中国药科大学生物制药专业，1991.9～1995.7

博士，中国药科大些微生物与生化药学，1995.9～2000.7

博士后，日本长崎大学药学院，2005.10～2007.9

主持“十二五”重大新药创制专项“安替安吉肽等重大多肽药物研发”（项目号2014ZX09508007）；参与“十二五”863计划项目“多肽分子药靶发现与药物设计技术”（项目号2012AA020304）；主持完成江苏省高校高新技术产业发展项目“微生物发酵法生产天然型脱落酸”（项目号JH02-014），通过江苏省科技成果鉴定，已与江苏双沟酒业股份有限公司合作工业化投产；完成企业合作项目“微生物发酵法生产辅酶Q10”、“天然型茄尼醇制备技术”等并已工业化；参与“II类新药螺旋藻多糖研制开发”，已进入临床。目前主要从事的课题有“微生物发酵法生产木糖醇”、“微生物发酵法生产番茄红素”、“酶转化法生产谷胱甘肽”、“酶转化法生产茶氨酸”以及“计算机辅助药物设计”等。

1.Liu, Shicai, Fan, Linlin, Sun, Jian, Lao Xingzhen*, Zheng Heng*. Computational resources and tools for antimicrobial peptides[J]. Journal of Peptide Science, 2017.23:4-12.

2.Fan, L. Sun J, Zhou M, Zhou J, Lao X, Zheng H*, Xu H*. DRAMP: a comprehensive data repository of antimicrobial peptides. Sci. Rep. 2016, 6, 24482

3.Tingting Yu, Xingzhen Lao* and Heng Zheng*. Pathogenic Roles of Cyclooxygenase-2 in Inflammation and Cancer. Mini-Reviews in Medicinal Chemistry. 2016, 16(15):1230-1243

4.Lao X， Bao J， Yu T， Li Q， Zheng H*. Structural and functional aspects of decorsin and its analog as recognized by integrin αIIbβ3. Journal of molecular modeling, 2016, 22(11): 281

5.Lao X, Li B, Liu M, Shen C, Yu T, Gao X*, Zheng H*. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects. Apoptosis. 2015, 20(10):1307-20.

6.Jing Xiao, Mi Fang, Yun Shi, Hui Chen, Bingzhen Shen, Jiao Chen, Xingzhen Lao, Hanmei Xu,* and Heng Zheng*. Identification and Validation Novel of VIM-2 Metallo-blactamase Tripeptide Inhibitors. Molecular Info, 2015. 34( 8): 559–567.

7.Jiao Chen, Hui Chen, Tong Zhu, Dandan Zhou, Fang Zhang, Xingzhen Lao*and Heng Zheng* Asp120Asn mutation impairs the catalytic activity of NDM-1 metallo-b-lactamase: experimental and computational study. Phys. Chem. Chem. Phys. 2014, 16, 6709-16.

8.Xiao-Hui Shang, Xiao-Yu Liu, Jian-Peng Zhang, Yun Gao, Bing-Hua Jiao, Heng Zheng* and Xiao-Ling Lu*. Traditional Chinese Medicine - Sea Urchin. Mini-Reviews in Medicinal Chemistry, 2014, 14(6):537-542

9.Jiao Chen, Yifang Liu, Tianyi Cheng,Xingzhen Lao, Xiangdong Gao, Heng Zheng*, Wenbing Yao*. A common binding mode that may facilitate the design of novel broadspectrum inhibitors against metallo-β-lactamases. Med Chem Res 2014,23:300-309

10.Lao X, Liu M, Chen J, Zheng H*. A tumor-penetrating Peptide modification enhances the antitumor activity of thymosin alpha 1. PLoS One. 2013 Aug 19 ;8(8):e72242. doi: 10.1371/ journal.pone.0072242.

11.Jiao Chen, Yifang Liu, Tianyi Cheng,Xingzhen Lao, Xiangdong Gao, Heng Zheng*, Wenbing Yao*. A common binding mode that may facilitate the design of novel broadspectrum inhibitors against metallo-β-lactamases. Med Chem Res 2013, DOI 10.1007/ s00044-013-0646-9

12.Shen B, Yu Y, Chen H, Cao X, Lao X, Fang Y, Shi Y, Chen J, Zheng H*. Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1). PLoS ONE, 2013, 8(5): e62955.

13.Liu JT, Lu XL, Liu XY, Gao Y, Hu B, Jiao BH, Zheng H*. Bioactive Natural Products from the Antarctic and Arctic Organisms. Mini-Reviews in Medicinal Chemistry, 2013, 13, 617-626

14.Jiao Chen, Rong Yu, Bingzheng Shen, Yan Xu, Yifang Liu, Heng Zheng* and Wenbing Yao*. Docking-based 3D-QSAR modeling of the inhibitors of IMP metallo-β-lactamase. Medicinal Chemistry Research 2013, 22（4）：1730-1739

获得国家发明专利5项，软件著作权3项